Infant Bacterial Therapeutics AB (publ) announced that the last premature infant has now been enrolled and recruitment to the Phase 2 study is now closed. The Phase 2 study (ClinicalTrial.gov identifier: NCT02472769), which is part of IBT's NEC prevention development program, is a randomized, double blind, parallel-group, dose escalation placebo-controlled multicenter study performed at neonatal intensive care units in the USA. The aim of the study is to investigate the safety and tolerability of two doses of the drug candidate (IBP-9414) administered to preterm infants. One-hundred and twenty (120) premature infants with birth weights ranging from 500g to 2,000g are included in the study. All patients in the study are treated with IBP-9414 or placebo for 14 days. The study ends after the last infant has been followed up for 6 months after the last dose administered.